Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 21-30 of 40 for Multiple myeloma

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. Alternate Doses and Dosing Schedules of Belantamab Mafodotin for the Treatment of Triple-Class Recurrent and/or Refractory Multiple Myeloma

    Jacksonville, FL

  2. A Study To Examine The Effects Of Novel Therapy Linvoseltamab In Combination With Other Cancer Treatments For Adult Patients With Multiple Myeloma That Is Resistant To Current Standard Of Care Treatments

    Rochester, MN

  3. KTX-100 MMSET Catalytic Inhibitor That Suppresses H3K36me2 In Patients With Relapsed And Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  4. A Study To Evaluate APG2575 Combined With Novel Therapeutic Regimens To Treat Subjects With Relapsed Or Refractory Multiple Myeloma And Immunoglobulin Light Chain Amyloidosis

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  5. A Study To Assess Adverse Events Of Intravenously (IV) Infused ABBV-383 In Adult Participants With Relapsed Or Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Rochester, MN

  6. A Study To Evaluate VSV-hIFNbeta-NIS To Treat Patients With Relapsed/Refractory Multiple Myleoma, Acute Myeloid Leukemia, Or T-cell Lymphoma

    Scottsdale/Phoenix, AZ, Rochester, MN

  7. MC230818 Understanding the mechanisms of clonal and non-clonal cytopenia following CAR-T therapy (MC230818)

    Albert Lea, MN, Scottsdale/Phoenix, AZ, Eau Claire, WI, Jacksonville, FL, La Crosse, WI, Mankato, MN, Rochester, MN

  8. Study Of SIM0500 Alone In Participants With Relapsed Or Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  9. A Study Comparing JNJ-79635322 And An Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody In Participants With Relapsed Or Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  10. A Study Of Belantamab Mafodotin Administered In Combination With Lenalidomide And Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, And Dexamethasone (DRd) In Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible For Autologous Stem Cell Transplantation (TI-NDMM)

    Scottsdale/Phoenix, AZ

.

Mayo Clinic Footer